explore -WSS

explore

author：focus 2025-10-01 18:33:23 - browse：66381

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

WSS

Report captures long Covid’s disabling effects and policy challenges

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

FDA advisory panel to debate high blood pressure devices

How to make over

National associations that represent hospice owe an apology

Listen: Vivek Ramaswamy's star turn & leaky drug data

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

How one medical school became remarkably diverse

Republicans love RFK Jr. What's that tell us about health in 2024?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Study: Spinal cord stimulation helps patients with paralysis walk again

BioMarin wins approval for gene therapy to treat hemophilia A

Trans patients at the end of life deserve respect and dignity

State Dept. review finds Biden bears some blame for Afghanistan failures

NIH tests clinical research in primary care with $30 million program

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Moderna says combo Covid

entertainment

Coercive sterilizations revealed by STAT prompt outrage

ALS patient reclaims some autonomy thanks to wearable 'robot'

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

As obesity drug market grows, telehealth companies court payers

Meadows told special counsel he could not recall Trump ever declassifying Mar

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

focus

Wikipedia

entertainment

focus